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Abstract
The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival 
ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required 
for optimizing outcome and quality of life. We aim at identifying mechanisms and associated molecular markers predic-
tive for benefit from radiotherapy (RT) or temozolomide (TMZ) in LGG patients treated in the randomized phase III trial 
EORTC 22033. As candidate biomarkers for these genotoxic treatments, we considered the DNA methylome of 410 DNA 
damage response (DDR) genes. We first identified 62 functionally relevant CpG sites located in the promoters of 24 DDR 
genes, using the LGG data from The Cancer Genome Atlas. Then we tested their association with outcome [progression-free 
survival (PFS)] depending on treatment in 120 LGG patients of EORTC 22033, whose tumors were mutant for isocitrate 
dehydrogenase 1 or 2 (IDHmt), the molecular hallmark of LGG. The results suggested that seven CpGs of four DDR genes 
may be predictive for longer PFS in one of the treatment arms that comprised MGMT, MLH3, RAD21, and SMC4. Most 
interestingly, the two CpGs identified for MGMT are the same, previously selected for the MGMT-STP27 score that is used 
to determine the methylation status of the MGMT gene. This score was higher in the LGG with 1p/19q codeletion, in this and 
other independent LGG datasets. It was predictive for PFS in the TMZ, but not in the RT arm of EORTC 22033. The results 
support the hypothesis that a high score predicts benefit from TMZ treatment for patients with IDHmt LGG, regardless of 
the 1p/19q status. This MGMT methylation score may identify patients who benefit from first-line treatment with TMZ, to 
defer RT for long-term preservation of cognitive function and quality of life.
Keywords Low-grade glioma · DNA methylation · TMZ · DDR genes · MGMT-STP27 · Randomized trial
Introduction
Optimal treatment strategy of patients with high-risk low-
grade glioma WHO grade II remains controversial [45, 
46]. The prognosis of patients varies greatly depending on 
clinical factors (tumor size, patient’s age) and the molec-
ular subtype, oligodendroglioma: mutant for isocitrate 
dehydrogenase 1 or 2 (IDH1 or 2; IDHmt) with co-deletion 
of the chromosomal arms 1p and 19q (codel); or astrocy-
toma: with (IDHmt), or without IDH mutation (IDH wild 
type) [7, 18, 36, 48]. Recent results of the Radiation Therapy 
Oncology Group trial (RTOG) 9802 phase III trial suggest 
that early administration of adjuvant chemotherapy [PCV, 
procarbazine, lomustine (CCNU), and vincristine] follow-
ing radiotherapy improves overall survival compared to RT 
alone [8]. Unfortunately, detailed molecular tumor character-
istics are not available for the RTOG trial, key information 
for adequate tumor classification according to the updated 
WHO classification 2016 [35]. The European Organisation 
for Research and Treatment of Cancer (EORTC) randomized 
phase III trial (EORTC 22033) was prospectively designed 
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to compare two treatment modalities, and to identify putative 
prognostic and predictive molecular markers. Initial clinical 
results have recently been reported [6]. There was no differ-
ence in progression-free survival for patients treated initially 
with radiotherapy alone or with dose-dense temozolomide 
[6]. Molecular subgroup analysis according to WHO clas-
sification 2016 showed no difference in outcome between 
the subpopulation of patients with IDHmt codeleted and 
IDHmt non-codeleted tumors when treated with radiother-
apy. In contrast, in the TMZ-treatment arm, patients with 
IDHmt codeleted tumors did better than the IDHmt and but 
non-codeleted subgroup. This implies a molecular differ-
ence rendering IDHmt codeleted tumors more sensitive to 
TMZ. This supports previous studies that reported improved 
responsiveness of 1p/19q co-deleted tumors to therapy; how-
ever, at the time IDH mutations were not yet discovered [23].
For individual treatment decisions and risk-adapted thera-
peutic strategies, it is it is crucial to identify the mechanisms 
and associated molecular factors predicting benefit from 
the distinct treatment modalities. For very poor prognosis 
patients an aggressive and combined modality treatment 
approach may be warranted, while for patients with a favora-
ble prognosis and long-term survival avoidance of long-term 
neurocognitive toxicities [14] is of importance.
The majority of low-grade glioma harbor an IDH1 or 
2 mutation, which is associated with a glioma CpG island 
methylator phenotype (G-CIMP) [16, 39]. This implies that 
a large number of genes are epigenetically inactivated by 
promoter methylation, impacting cancer-relevant pathways 
and potentially modulating treatment response. Given that 
the patients in EORTC 22033 were randomized to distinct 
genotoxic treatments, we hypothesized that variations in 
DNA repair proficiency, associated with G-CIMP linked 
aberrant promoter methylation, may explain differences in 
outcome in the two treatment arms. With a focus on IDHmt 
LGG, we set out to assess the DNA methylome of DNA 
damage response (DDR) genes that includes MGMT, to 
find predictive factors for treatment. We further aimed at 
uncovering potential DNA repair vulnerabilities that may be 
exploited as the “Achilles’ heel” of the tumors, actionable by 
novel treatment approaches [21].
Materials and methods
Patient samples
Tumor specimens (formalin fixed paraffin embedded [FFPE] 
or frozen) were collected from patients treated in the phase 
III trial EORTC 22033 (NCT001828199) [6] for high-risk 
low-grade glioma. Non-tumoral brain tissue (n = 5, FFPE) 
was available from epilepsy surgery. Patients agreed and 
signed written informed consent for translational research 
according to institutional and international guidelines and 
regulations. The trial design of EORTC 22033 comprised a 
2-step process: first, patients were registered and tumor tis-
sue was submitted for central pathology review and determi-
nation of the deletion status of chromosome 1p (stratification 
factor). Second, at the time when at least one high-risk fea-
ture was present (age > 40 years, progressive disease, tumor 
size > 5 cm, tumor crossing the midline, or neurological 
symptoms) patients were randomized to focal radiotherapy 
(RT, 50.4 Gy in 28 fractions of 1.8 Gy) or dose-dense temo-
zolomide treatment (TMZ, 75 mg/m2, 21/28 days, maximum 
of 12 cycles) [6].
DNA methylation analysis
For genome-wide DNA methylation analysis, DNA was iso-
lated from macro-dissected tumor tissue (frozen samples: 
DNeasy Blood & Tissue Kit, Qiagen; FFPE samples: EX-
WAX™ Paraffin-embedded DNA Extraction Kit, S4530; 
Merck KGAa) and quantified (Quant-iT™  PicoGreen® 
dsDNA Assay Kit, #P7589, Life Technologies). Tumor DNA 
samples of 150 patients passing a PCR-based quality control 
(Infinium HD FFPE QC Assay Protocol) were subjected to 
bisulfite treatment (EZ DNA Methylation-Gold™ Kit, Zymo 
Research) as previously described [27], and were analyzed 
on the Human Methylation 450K BeadChip (Illumina, San 
Diego CA, USA) according to the manufacturer’s protocol 
at the Genomics platform of the University of Geneva. FFPE 
samples were analyzed in separate batches after pretreatment 
with the restoration kit as recommended (Illumina). The 
dataset is available under the accession number GSE104293 
at GEO (http://www.ncbi.nlm.nih.gov/geo/).
External datasets
External datasets comprised the LGG dataset from The Can-
cer Genome Atlas (TCGA; n = 197; 90 WHO grade II, 106 
WHO grade III, 1 unspecified WHO grade) [7] and a set of 
anaplastic glioma (AGlioma, WHO grade III, n = 227; GEO 
accession number GSE58218) [50]. The TCGA dataset was 
randomly split into two sub-datasets, called TCGA-1 and 
TCGA-2 (stratified by age, 1p/19q codeletion status, WHO 
grade, CIMP status, and overall survival), to obtain a test and 
a validation cohort for marker selection and construction of 
a predictive model for purity estimation. (dbGaP accession 
number phs000178.v9.p8; http://cance rgeno me.nih.gov).
Data processing
The normalization [20] for Illumina HM-450K arrays 
included NOOb background correction, dye-correction 
(chemistry I vs II) and RUV-2 step (removal of unwanted 
variation) based on control probes using the function 
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preprocessFunnorm from the R package minfi [3]. DNA 
methylation was summarized by M values [15]. The Com-
Bat procedure [25] was used to limit experimental variation 
and batch effects across the four datasets.
Probe selection
CpG probes with detection p values of more than 0.01, 
located on the sex chromosomes, or in SNPs were removed. 
A three Gaussian mixture model based on M values was used 
to establish the DNA methylation status of probes in non-
tumoral brain tissue (NTB) in order to remove methylated 
and hemi-methylated probes. Then selection of methylation 
probes was restricted to CpGs located in gene promoters 
within 1500 nucleotides up- or down-stream of the tran-
scription start site (TSS). The gene locations were based on 
Homo sapiens data from UCSC build hg19. The list of DDR 
genes was adopted from Pearl et al. [41]. A list of 167235 
CpGs was detected in promoter regions and 101981 CpGs 
were considered as unmethylated in non-tumoral brain tis-
sue. CpG methylation was defined as “functional” when the 
correlation between CpG methylation and expression of the 
corresponding gene was negative in both datasets TCGA-1 
and TCGA-2, with a Pearson correlation coefficient infe-
rior or equal to − 0.3 (corresponds to approximately 10% of 
explained variance) and an fdr-corrected p value not superior 
to 0.1 for a test of the null hypothesis of correlation equal 
to 0.
MGMT promoter methylation and the MGMT 
methylation score
The DNA methylation status of the MGMT promoter and 
the MGMT score (logit-transformed probability) were deter-
mined based on HM-450K data as previously reported [4, 5]. 
In brief, the M values of the methylation probes cg12434587 
and cg12981137 were used as input into the logistic regres-
sion model (MGMT-STP27). A cut-off of 0.358 is used for 
classification into MGMT methylated and unmethylated pro-
moter status, respectively [4, 5].
Expression
Gene expression from RNAseq data (Level 3) was quantified 
for the transcript models using RSEM [33] and normalized 
within-samples to a fixed upper quartile for TCGA. Further 
details are available at the DCC data portal of TCGA. Gene-
level data were restricted to genes expressed in at least 70% 
of samples. The complete dataset was normalized by the 
VOOM procedure [30], and it was split according to the 
TCGA-1 and 2 DNA methylation datasets.
Molecular subtype
In all datasets the samples were classified into the three 
molecular glioma subtypes according to the revised WHO 
classification 2016 [36] using HM-450K data. The G-CIMP 
status was determined by unsupervised clustering (Ward’s 
algorithm with Euclidean distance) as previously reported 
[5]: the G-CIMP status served as approximation for the IDH 
mutation status, as this information was not available for all 
samples in any of the datasets. The IDH mutation status was 
available for 123/132 patients in EORTC 22033, 194/227 
patients in AGlioma, 96/201 patients in TCGA-1, and 
99/197 patients in TCGA-2. The 1p/19q codeletion status 
was assessed using the combined intensities for methylated 
and unmethylated signals and circular binary segmentation 
to detect copy number aberration (CNA) events as previ-
ously described [4]. Baseline characteristics are described 
in Table 1 for all four datasets.
Table 1  Clinical and molecular 
variables of the EORTC 22033 
dataset and the external glioma 
datasets (WHO grade II and III) 
used for this study
a Chi-squared test
b Kruskal and Wallis test
c IDH status inferred from G-CIMP status; see Methods
Variable Modality EORTC 22033 TCGA-1 TCGA-2 AGlioma p value
N 132 201 197 227 –
Sexa M 74 114 111 72 0.6234
F 58 87 86 42
Age (year)b Median 43 41 40 42 0.3683
Min 20 17 14 23
Max 71 87 75 74
Gradea II 132 95 96 0 < 0.0001
III 0 106 101 227
Subtypea,c IDHwt 12 37 36 50 0.0105
IDHmt non-codel 80 108 107 97
IDHmt codel 40 56 54 80
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Estimation of tumor purity based on HM‑450K
The tumor purity of each sample was estimated by a predic-
tive model based on DNA methylation information using the 
purity estimation by the ABSOLUTE procedure available for 
the LGG TCGA dataset [7]. The split LGG TCGA datasets 
served as training and validation sets, respectively. The pre-
diction of the purity of the samples was provided by a Sparse 
Partial Least Squares model (SPLS), where unmethylated 
(β-median < 0.2) CpG-probes located in intergenic regions 
were the predictors and ABSOLUTE purity estimation cor-
responded to the response (after arcsin-square-root trans-
formation). The SPLS regression used the PLS-NIPALS 
algorithm (maximize covariance between variable of inter-
est and predictors) with lasso regularization to reduce the 
number of dimensions and to limit multicollinearity [31]. 
The final model was used to predict purity (HMP index) for 
the four datasets (details in supplementary Fig. S1, Online 
Resource 1).
Statistical analysis
Differential DNA methylation and differential gene expres-
sion between codeleted and non-codeleted IDHmt tumors 
were tested by moderated t test (R package limma) on M 
values [15] and normalized expression, respectively. Beta-
values, equivalent to methylation fraction, were used to 
complement M values as a measure of effect size. The set of 
differentially methylated positions (DMPs) was established 
with a fold change cut-off for the Beta-value of 0.1 and for 
the fdr-adjusted p values of 0.1.
This analysis was performed for the four datasets and 
the list of candidate DMPs was given by the intersec-
tion of the four results. Comparison of DNA methylation 
patterns were investigated by a simultaneous analysis of 
several tables based on a principal component analysis 
algorithm called STATIS [29]. This method enables the 
analysis of the relationship among data tables with the 
same variables (CpG-probes) and combines them into a 
compromise matrix corresponding to the optimal agree-
ment between the data. Briefly, STATIS can be sepa-
rated into three steps: the interstructure, the analysis of 
the compromise and the intrastructure. The interstructure 
consists of the comparison of the table by RV-coefficient 
[44] and the construction of the compromise. The RV-
coefficient measures the similarity between two tables: 
the values 0 and 1 correspond to unperfect and perfect 
matching between the two tables, respectively. A per-
mutation test based on the first eigenvalue of the inter-
structure was developed to evaluate the strength of the 
relationship among datasets. The analysis of the com-
promise yields a reference system providing an optimal 
averaged representation of the columns (CpG-probes). 
The representation of the rows (samples) and columns 
(CpG-probes) of each table are obtained by projection 
onto the reference system (intrastructure). These analyses 
and graphics were performed using the R package ade4 
[12].
Differential gene expression was considered as significant 
when the absolute fold change was superior or equal to log2 
(1.2) and the fdr-adjusted p value inferior or equal to 0.1. 
Association between PFS and CpG-probes were assessed 
using the Cox proportional-hazards regression model and 
the log-likelihood ratio test (LRT). The additive models 
included CpG-probes, treatment or treatment and 1p/19q 
codeletion status as covariables, and contained the interac-
tion term between CpG-probes and treatment. Time was 
taken from the date of surgery (not randomization as in the 
clinical trial) and an event (treatment failure/progression or 
death) after randomization to RT or TMZ. The predictive 
effect of markers was assessed by testing the interaction 
between treatment and CpG-probes.
The mean comparison between groups was performed 
by t test or by one-way anova. The Wald test with robust 
estimation of the covariance matrix was used when heter-
oskedasticity was suspected [52]. All analyses and graphi-
cal representations were performed using R-3.4.1 (https ://
www.R-proje ct.org/).
Results
General description
Tumor DNA methylation profiles were available for analy-
sis from 132 patients of 477 (28%) randomized in EORTC 
22033 [6]. Classification of the samples into WHO sub-
groups based on the methylation data identified 40 (30.3%) 
G-CIMP 1p/19q codel (‘oligodendroglioma’), 80 (60.6%) 
G-CIMP 1p/19q non-codel (‘astrocytoma, IDHmt’), and 
12 (9.1%) non-CIMP (‘astrocytoma, IDHwt’) tumors. The 
proportions of the molecular WHO subgroups were slightly 
different from those in the clinical trial subpopulation with 
available molecular classification (n = 318) [6]. The com-
parison of clinical baseline characteristics between this 
subset and the rest of the trial population is summarized 
in the supplementary Table S1 (Online Resource.1). There 
were less biopsy-only patients in our cohort, as expected, 
and the association of the 1p/19q codeletion status and PFS 
was different.
The IDH mutation status was not available for all tumor 
samples in any of the four datasets (available for 512/757; 
see ‘Molecular subtype’ in Methods), therefore, we used 
the G-CIMP status as proxy for the IDH mutation status. 
Where both were available, G-CIMP and IDH1/2 muta-
tion information agree almost perfectly, 100% for TCGA-1 
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and TCGA-2, 97.56% for EORTC 22033, and 97.42% for 
AGlioma. Throughout the manuscript we will refer to ‘IDH 
status’. Table 1 summarizes the proportions of the molecu-
lar WHO subtypes and basic clinical characteristics of the 
patients in the four datasets (EORTC 22033, TCGA1 and 2, 
AGlioma) used in the subsequent analyses.
The DDR methylome of glioma
We aimed at identifying DDR genes down-regulated by 
aberrant promoter methylation that could either serve as bio-
markers for outcome prediction or inform on inherent DNA 
repair vulnerabilities amenable to treatment. To this end the 
split TCGA LGG datasets (which includes both grade II 
and III glioma) were used for the selection of functionally 
methylated CpGs located in the promoters of DDR genes 
as outlined in supplementary Fig. S2 (Online Resource 1). 
Functional methylation was defined under the postulate that 
DNA methylation of the promoter down-regulates expres-
sion. The HM-450K chip annotates 3749 CpGs as located in 
the promoter regions of 410 DDR genes. Thereof 62 CpGs 
satisfied the criteria of functional methylation in both data-
sets, identifying 24 DDR genes (supplementary Table S2, 
Online Resource 2). The functionally methylated probes 
are displayed for the EORTC 22033 dataset in a heatmap 
in Fig. 1, annotated with key clinical and molecular infor-
mation. The heatmap visualizes the high concordance of 
CpG methylation within the individual genes. This subset 
of methylation probes largely separated the LGG according 
to the molecular subtypes.
For the subsequent data analyses, we only considered 
IDHmt LGG. IDH wild-type (IDHwt) astrocytoma were rare 
in our cohort (n = 12); furthermore, they are considered a 
heterogeneous group that may belong to other tumor enti-
ties [43].
First, we aimed at demonstrating the robustness of the 
methylation patterns of interest across the four datasets as a 
prerequisite for the validity of the following analyses. The 
two TCGA datasets (TCGA1 and 2) were highly similar in 
regard to the functional methylation of the selected 62 func-
tional CpGs in DDR genes, as determined by comparing 
their Pearson correlation between gene methylation and gene 
expression [RV-coefficient = 0.92 (max. achievable value 
is 1), p value = 0.001 for 999 permutations; supplementary 
Fig. S3, Online Resource 1].
Next, a common DNA methylation pattern among the 
four datasets was confirmed for the 62 CpGs (Fig. 2a, STA-
TIS interstructure, global permutation test, simulation p 
value < 0.001 for 999 permutations). In concordance, pair-
wise comparison of the methylation patterns in the four data-
sets (TCGA-1 and 2, AGlioma and EORTC 22033) showed 
high similarity with all RV coefficients > 0.8 (STATIS 
analysis) (Fig. 2a).
An overview of the correlations between CpGs of all four 
datasets is visualized in Fig. 2b showing the consensus rep-
resentation of the functional CpG probes (first two axes). 
Genes featuring multiple functionally methylated CpGs 
in their promoter, such as UBB, MLH3, MGMT, POLE4 
and BCAS2, highlight the high concordance of methyla-
tion among their CpGs, confirming the robustness of DNA 
methylation patterns at the gene scale and across datasets 
(Fig. 2b). This consensus gene organization indicates a 
strong DNA methylation gradient implying a higher extent 
of methylation in IDHmt codeleted tumors, as compared to 
IDHmt non-codeleted tumors (Fig. 2b). Accordingly, differ-
ences between the IDHmt codeleted and non-codeleted sub-
populations were observed for all four datasets (Fig. 2d–g). 
The separation of the IDHmt codeleted and non-codeleted 
subgroups across all four datasets is also demonstrated by 
cluster analysis (Fig. 2c).
The functional probeset included MGMT that is of known 
relevance for DNA repair associated with TMZ treatment-
induced lesions, and the putative mismatch repair (MMR) 
gene MLH3. Other functionally methylated DDR genes 
identified have been associated with nuclear excision repair 
(NER), e.g. POLE4, or homologous recombination (HR), 
e.g. RDM1. The gene encoding UBB was selected with a 
large number of functionally methylated CpGs. It is involved 
in regulation of chromatin structure and protein degrada-
tion affecting many pathways. The identified 24 functionally 
methylated genes are visualized in the context of the DDR 
network in Fig. 3. No enrichment for specific repair path-
ways was observed.
DDR genes associated with 1p/19q codeletion 
in LGGs
The molecular subtypes have been associated with dif-
ferential benefit from TMZ vs RT; e.g. patients with non-
codeleted IDHmt LGG did not benefit as much from TMZ 
as from RT [6], suggesting differences in the proficiency 
of some DNA repair systems. Therefore, we assessed dif-
ferential DNA methylation (DM) between codeleted and 
non-codeleted IDH-mutant samples for CpGs located in the 
promoters of DDR genes. This identified 36 differentially 
methylated positions (DMP) corresponding to 19 genes 
(supplementary Fig. S4, Online Resource 1; supplementary 
Table S2, Online Resource 2); one-third of them belong 
to 4 functionally methylated DDR genes (10/36 CpGs: 2 
CpGs for MGMT, 5 CpGs for POLE4, 1 CpG for MVP, and 
2 CpGs for SMC1B; Fig. 3, supplementary Table S2, Online 
Resource 2).
Gene expression analyses in the TCGA-1 and 2 datasets 
identified 74 of 410 DDR genes as differentially expressed 
(DE): 39 genes down-regulated in the codeleted group, and 
35 up-regulated (supplementary Table S3, Online Resource 
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3 and supplementary Fig. S5, Online Resource 1). The top 
up-regulated DDR gene in IDHmt codeleted tumors was 
hTERT, whose activating promoter mutations are known 
to be correlated with overexpression and 1p/19q codeletion 
(supplementary Table S3, Online Resource 3) [2]. Three 
downregulated DDR genes (MGMT, POLE4 and SMC1B) 
were differentially methylated, 22 genes are located on 
either chromosome 1p or 19q, and downregulation may be 
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Fig. 1  Heatmap representation of normalized DNA methylation of 
the 62 functional DDR CpGs in EORTC 22033. The dendrogram was 
established by hierarchical classification using Ward’s algorithm and 
Euclidean distance. Annotation of the 132 LGG samples comprises: 
MGMT methylation score (purple–blue color gradient, higher score 
more purple), purity estimation (HMP index, orange color gradient, 
more pure, more dark), copy number status for 10q26.3 region (grey, 
no change; red, amplification; blue, deletion), 1p/19q codeletion sta-
tus (green, codeleted; grey, non-codeleted), CIMP status (green, non-
CIMP; red, CIMP), IDH1 and IDH2 mutation status (green, wild 
type; red, IDH mutated; white, not determined), sex (red, female; 
grey, male), DNA methylation status of MGMT (MGMT-STP27, 
unmethylated, blue; methylated, red), tissue type (green, frozen; red, 
FFPE) and Batch (different colors). The 62 functional DDR CpGs 
are indicated on the right. The corresponding probe names are listed 
in supplementary Table S2 (Online Resource 2). The location on the 
chromosome (chr) arm, and the status as differential methylation 
position (DMP, blue; differentially methylated between codeleted and 
non-codeleted tumors) are indicated on the left
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attributed to gene dosage (loss of one allele). No significant 
enrichment of a given DDR pathway was observed using 
gene set enrichment analysis (GSEA) (based on mean-rank 
gene set test, not shown).
Predictive markers for progression‑free survival 
in IDHmt LGG of EORTC 22033
The EORTC 22033 dataset allows for correlation of gene 
methylation with outcome and influence of treatment 
(a) (b)
(c)
(d) (e) (f) (g)
Fig. 2  Similarity of functional DNA methylation patterns of IDHmt 
LGG among the four datasets. a The four DNA methylation datasets, 
using the common 62 functional DDR CpGs, were analyzed simulta-
neously by the STATIS procedure to determine similarity. First, the 
global comparison of the four datasets is provided by the interstruc-
ture, based on the pairwise comparisons (RV coefficients, all > 0.8). 
Each dataset is represented by an arrow and the small angles between 
arrows indicate high similarity between datasets (global permutation 
test, simulation p value < 0.001 for 999 permutations). b The com-
promise (PCA-like) analysis of the functional DDR CpGs across the 
datasets provides an optimized average representation. It gives a gen-
eral view of the correlations between the functional CpGs (see sup-
plementary Table S2, Online Resource 2, for the list of corresponding 
CpG probes). The gradient of CpG methylation is indicated with the 
red arrow. The CpGs detected as significantly differentially methyl-
ated between codeleted and non-codeleted groups are represented by 
blue arrows. The representation of the patients on the two first axes of 
the compromise analysis is given for each dataset (d, e, f, g). The first 
axes mainly separates the samples according to the codeletion status, 
as visualized by the inertia ellipse [CD-II, grade II codeleted (blue); 
CD-III, grade III codeleted (light blue); N-II, grade II non-codeleted 
(orange); N-III, grade III non-codeleted (red)]. c In line, the clus-
tering of the molecular subgroups of the four datasets separates the 
codeleted (blue) from the non-codeleted (red) samples (Ward’s algo-
rithm and Euclidean distance derived from STATIS coordinates and 
is visualized in a dendrogram)
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modality. In 120 IDHmt patient samples of EORTC 22033, 
we tested the 62 functionally methylated CpGs identified 
in 24 DDR genes for their association with PFS depend-
ing on treatment (supplementary Table S4, Online Resource 
4). This was investigated by testing for significance of the 
treatment–biomarker interaction term in a Cox proportional-
hazards survival model. The analysis yielded 7 CpGs located 
in the promoters of 4 DDR genes: 3 of 6 functional CpGs 
in MLH3, 2 of 6 in MGMT, and 1 of 2 in SMC4 and 1 of 
1 in RAD21, respectively. The expected survival by treat-
ment arm, in function of the continuous CpG methylation 
values, is visualized in the supplementary Fig. S6 (Online 
Resource 1). The results suggested that the two leading 
CpGs for MGMT are prognostic for PFS in the TMZ arm 
only, while the top MLH3 CpGs and those from SMC4 and 
RAD21 are prognostic in the radiation arm only. The same 
7 CpGs were retained when the model included the codele-
tion status as an adjustment factor (supplementary Table S4, 
Online Resource 4).
The two CpGs selected for MGMT were identical to 
those we previously selected for the logistic regression 
model to calculate the MGMT methylation score used by 
the MGMT-STP27 classifier [4, 5]. The interaction term 
with treatment was also significantly different from zero for 
this score [Table 2, HR = 0.755, 95% CI (0.5786, 0.9772), p 
value = 0.033, Fig. 4a], independently whether the codele-
tion status was added to the model (Table 2). As example, 
Kaplan–Meier representations are given for two cut-offs 
(first and third quartiles of MGMT score distribution) that 
illustrate the interaction effect between high MGMT meth-
ylation and treatment with TMZ in EORTC 22033 (Fig. 4b, 
c). Of note, the codeletion status was not significantly 
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?
Fig. 3  DDR networks based on pathways as defined in Pearl et  al. 
[40]. DDR genes identified as functionally methylated are indicated 
and marked in green (FP). Functional DDR genes that are differen-
tially methylated between IDHmt codel and IDHmt non-codel LGG 
are marked in red (FDMP)
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associated with PFS among IDHmt patients in a univari-
able model (p = 0.16, log rank test). 
The MGMT methylation score was significantly higher in 
the codeleted than in the non-codel IDHmt glioma in all four 
datasets (Fig. 5). A scatter plot of the MGMT methylation 
score and MGMT expression visualizing the negative cor-
relation is displayed for the three molecular LGG subtypes 
of the TCGA dataset, for which RNA-seq expression data 
are available (supplementary Fig. S7, Online Resource 1).
It has been reported that tumor purity, “contaminated” 
by microglia, non-tumoral brain tissue, and tumor infiltrat-
ing cells, differs between histologic subtypes of LGG [1] 
and may therefore be a confounding factor for estimating 
subtype dependent differences of DNA methylation. In order 
to exclude that the higher MGMT methylation score in the 
codeleted tumors is driven by higher purity, we estimated 
sample purity based on the methylation data (see methods). 
Significant differences between the codeleted and non-
codeleted IDHmt tumors (p value < 0.01, t test, supplemen-
tary Fig. S8, Online Resource 1) were observed in all four 
datasets (EORTC 22033, TCGA1 and 2, AGlioma). These 
results confirm that codeleted IDH-mutant tumors appear 
more pure. A significant but only weak association between 
the MGMT score and tumor sample purity was detected for 
EORTC 22033 (p value = 0.0013, Wald test based on robust 
estimation). The purity index explained 7.1% of the vari-
ance. Adjusting the MGMT score for the purity effect using 
a linear model had only a minor effect on the association of 
the MGMT score with the molecular subtype (supplementary 
Fig. S9, Online Resource 1) and led only to minor modi-
fications in the Cox proportional-hazards models and the 
significance tests in EORTC 22033 [Table 2, HR = 0.7451, 
95% CI (0.5655, 0.9817), p value = 0.037]. Similarly, a 
weak association between the MGMT score and purity was 
observed for the TCGA-1 (p value < 0.0001, R2 = 7.1%) and 
TCGA-2 (p value < 0.0001, R2 = 6.7%) datasets, whereas 
the explained variance was higher in the AGlioma dataset 
(R2 = 22.6%, p value < 0.0001).
Discussion
Here we set out to investigate whether epigenetic inactiva-
tion of DDR genes affected the patients’ benefit (PFS, time 
lapse from initial surgery to treatment failure upon rand-
omization to RT or TMZ therapy) from genotoxic treatment 
with either RT or TMZ in EORTC 22033. Furthermore, we 
aimed at uncovering potential DDR pathway vulnerabilities 
as potential drug targets. Through multidimensional analyses 
of the molecular LGG dataset of TCGA, we identified 24 
candidate DDR genes that are functionally downregulated by 
aberrant promoter methylation. Importantly, promoter meth-
ylation of four of these DDR genes was predictive for benefit 
(PFS) from either alkylating agent chemotherapy (TMZ) or 
RT in EORTC 22033.
The most prominent functionally methylated gene was 
MGMT that is known as predictive factor for benefit from 
TMZ in GBM [22]. Most IDHmt LGG have a methylated 
MGMT gene promoter [4–6, 18]. In line, in this study all 
IDHmt 1p/19q codel LGG, and almost 90% of the IDHmt 
non-codel glioma were MGMT methylated [6]. Due to 
this nested relationship, the mechanistic impact of MGMT 
Table 2  Multi-variable models for progression-free survival (PFS)
Values in bold are statistically significant
TRT treatment
Variable Model Variable Coefficient HR SE z value p value
MGMT methylation score (raw) Model 1 MGMT 0.0502 1.0515 0.0912 0.5502 0.5822
TRT (TMZ) − 0.0797 0.9234 0.2770 − 0.2876 0.7736
MGMT × TRT − 0.2851 0.7519 0.1337 − 2.1324 0.0330
Model 2 CODEL (CD) − 0.1988 0.8197 0.3281 − 0.6060 0.5445
MGMT 0.0667 1.0689 0.0948 0.7030 0.4821
TRT (TMZ) − 0.0462 0.9548 0.2821 − 0.1639 0.8698
MGMT × TRT − 0.2807 0.7553 0.1342 − 2.0910 0.0365
MGMT methylation score after remov-
ing effect of purity (HMP index)
Model 1 MGMT 0.0715 1.0741 0.1028 0.6960 0.4864
TRT (TMZ) − 0.1778 0.8371 0.2728 − 0.6519 0.5145
MGMT × TRT − 0.2942 0.7451 0.1407 − 2.0910 0.0365
Model 2 CODEL (CD) − 0.2464 0.7816 0.3168 − 0.7778 0.4367
MGMT 0.0895 1.0936 0.1044 0.8570 0.3915
TRT (TMZ) − 0.1299 0.8782 0.2790 − 0.4656 0.6415
MGMT × TRT − 0.2910 0.7475 0.1404 − 2.0720 0.0383
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promoter methylation on treatment-related outcome remains 
unclear. The two MGMT CpG probes identified in this study 
as predictive, are also the ones selected in the MGMT-STP27 
classifier to calculate the score, and both are predictive for 
benefit from treatment with alkylating agents in GBM [5]. 
Most importantly, in this study an increased MGMT meth-
ylation score (~ extent of MGMT methylation) was predic-
tive for benefit under TMZ treatment, but not under RT. 
0.10.20.30.4
0.5
0.6
0.7
0.8
0.9
0.1
0.2
0.3
0.4
0.5
0.60.
7
0.
8
0.
9
RT TMZ
50 100 150 50 100 150
−2.5
0.0
2.5
5.0
7.5
10.0
Time (months)
M
G
M
T 
sc
or
e
(a)
+
++ +
+
++
+
++
+ ++
+
+ ++
+
++ +
+++
+
p = 0.97
0.00
0.25
0.50
0.75
1.00
0 50 100 150 200
Time (months)
P
ro
gr
es
si
on
-F
re
e 
S
ur
vi
va
l (
%
)
(b)
13 6 1 0 0
32 13 2 1 0
18 10 0 0 0high
intermed
low
0 50 100 150 200
Time (months)
Number at risk
+++
+
+
+
+++++
++ +
+
+
+
++
+
+
p = 0.014
0.00
0.25
0.50
0.75
1.00
0 50 100 150 200
Time (months)
P
ro
gr
es
si
on
-F
re
e 
S
ur
vi
va
l (
%
)
(c)
17 8 1 0 0
28 17 3 0 0
12 9 3 1 0high
intermed
low
0 50 100 150 200
Time (months)
Number at risk
1st Qu.
3rd Qu.
0.25
0.50
0.75
Progression−Free
Survival (%)
high
intermediate
low
Fig. 4  Progression-free survival in function of the MGMT methyla-
tion score. a The simulation of progression-free survival (%, PFS) 
is based on the Cox proportional-hazards model and PFS (%), and 
is shown in function of time (month) and the MGMT methylation 
score for patients randomized to treatment with radiotherapy (RT) 
or temozolomide (TMZ). The graphics illustrate a three-dimensional 
Kaplan–Meier plot, where the MGMT methylation score and time are 
explanatory variables and the colors of the gradient complemented 
by contour lines indicate progression-free survival (%). As examples, 
two cut-offs (first and third quartiles of MGMT score distribution) 
were used to define three groups of methylation (low, intermediate, 
high) for patients from EORTC  22033. The two cut-offs are indi-
cated by dashed lines in a. Kaplan–Meier plots illustrate the associa-
tion between a high MGMT score and PFS in the treatment arms, RT 
(b) and TMZ (c). The p values are given by log-rank test. The KMs 
in b and c confirm the significant interaction between TMZ and the 
MGMT score (Table 2)
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The MGMT score was significantly higher in codeleted vs 
non-codeleted IDHmt tumors. This is in agreement with the 
clinical observation of a worse PFS of IDHmt non-codeleted 
patients when treated with TMZ, while there was no differ-
ence when treated with radiotherapy [6].
Fig. 5  MGMT score in function of the molecular subtype in LGG. 
The MGMT methylation scores for the three distinct molecular sub-
types (wt, CIMP-/IDHwt;  IDHmt, CIMP+ non-codel;  IDHmt codel, 
CIMP+ codel) separated by WHO tumor grade, are shown for the 
four datasets (EORTC 22033, TCGA1 & 2, AGlioma). The p values 
of the comparison between codeleted and non-codeleted samples are 
based on the Welch’s t test for each dataset. The dashed line indicates 
the MGMT-STP27 cut-off [logit(0.358)]
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There are some notable differences of MGMT meth-
ylation in LGG compared to GBM. In IDHmt LGG the 
MGMT methylation score summarizes methylation of two 
MGMT alleles, while GBM harbor frequent loss of one 
allele (> 80%; CHR 10q26) [4], and the methylation of the 
retained allele informs on inactivation of the MGMT gene. 
Thus, in presence of two alleles, the detection of methylation 
may indicate methylation of both alleles, or complete meth-
ylation of only one allele, leaving the gene on the remain-
ing allele functional. Thus, a high MGMT methylation score 
increases the probability of inactivating both MGMT alleles.
The relevance, and mechanistic implications of epigenetic 
silencing, of the other three genes identified as predictive for 
benefit from RT, are less clear. Methylation of three CpGs in 
the MLH3 promoter appear predictive for benefit from RT. 
MLH3 is usually associated with MMR, although it seems to 
play only a minor role in this process, and may not actually 
be required [9, 26]. Germline mutations in MLH3 have been 
associated with the Lynch syndrome, although not fulfilling 
the Amsterdam I criteria, and with an unclear clinical role 
[42]. Frequent MLH3 methylation in IDHmt LGG has been 
reported previously [32]; MLH3 may be involved in other 
cancer-relevant processes [9].
For the other two genes only one CpG each was asso-
ciated with outcome and treatment. RAD21 is involved 
in DSB repair, and haploinsufficiency has been reported 
to enhance radiosensitivity in a mouse model [51], in line 
with a potential predictive value for RT. SMC4 is part of the 
condensin complexes I and II that are essential for chromo-
some assembly and segregation, and is involved DSB repair 
[34]. Genes encoding members of the cohesion complex are 
targeted by deletion or mutation in 16% of LGG/GBM, sug-
gestive of a glioma genesis relevant role of the pathway [11].
The search for biomarkers identifying potential vul-
nerabilities in repair pathways yielded a number of can-
didates. Twenty-four functionally methylated DDR genes 
were confirmed in three independent LGG datasets, and 
some may open novel treatment options. Most interestingly, 
recent encouraging results from clinical trials have raised 
the interest in targeting DNA repair vulnerabilities in can-
cer. Responses to the PARP inhibitor olaparib have been 
observed in metastatic prostate cancer with defects of repair 
genes (mutations, deletions) [37]. In breast cancer inactiva-
tion of BRCA1 and/or 2 by promoter methylation is currently 
considered for treatment with the same PARP inhibitor in a 
trial (clinicaltrial.gov, NCT03205761). Veliparib is currently 
undergoing phase 3 evaluation in GBM in a randomized 
Alliance trial (NCT02152982). Along the same lines, PARP 
inhibitors may be useful for LGG patients with promoter 
methylation of MLH3, or XRCC1 that when defective have 
been reported to render cells sensitive to PARP inhibition, 
and are therefore discussed as being potentially amenable to 
PARP inhibitor treatments [37, 38].
Of interest, XRCC1 is located on CHR 19q, hence 
haploinsufficient in the IDHmt codeleted tumors. Con-
sequently, detection of promoter methylation informs on 
the silencing of the remaining allele. Furthermore, based 
on predictions for druggability of DDR genes (see recent 
reviews by Pearl et al. [41] and Stover et al. [47]), five of 
our functionally methylated DDR genes (RPA2 SMARCA5, 
SMC4, XRCC1, mTOR) may warrant further investiga-
tions. Targeting of mTOR is currently under investiga-
tion in a trial for LGG with or without TMZ treatment 
(NCT02023905).
The current efforts to promote the HM-450K methyla-
tion platform (or the more recent version, EPIC) as a diag-
nostic tool for classification of brain tumors [10, 17], will 
make the here identified markers potentially evaluable in 
routine diagnostics and may allow validation of the pre-
sented results. This diagnostic tool integrates the MGMT 
methylation score as part of the MGMT-STP27 classi-
fier [10]. However, most quantitative assays for MGMT 
methylation analysis, such as methylation-specific pyrose-
quencing should be amenable to determine the extent of 
methylation. We previously showed good concordance 
between the HM-450K based MGMT-STP27 classifier 
and pyrosequencing using the respective cut-offs for glio-
blastoma [5].
We have focused our investigations to epigenetically 
silenced DDR genes, since promoter methylation seems to 
be quite stable in tumors and may not easily change under 
treatment [19, 28]. While mutations in DDR genes are 
exceedingly rare in chemo-naive LGG, with the exception of 
TERTp and ATRX [48], there are other mechanisms attenu-
ating relevant DNA repair systems. Of particular interest 
for lower grade glioma is the recently described inhibitory 
effect of the oncometabolite 2-hydroxy glutarate (2HG) on 
the α-ketoglutarate-dependent ALKBH repair enzymes that 
are involved in direct DNA repair, including TMZ induced 
lesions [24, 49]. 2HG, produced by the neomorphic func-
tion of the IDH1 and 2 mutants is accumulated to high con-
centrations in the respective tumors [13] and may confer 
sensitivity to alkylating agent chemotherapy and protracted 
natural history.
In conclusion, our analyses suggest that a high MGMT 
methylation score predicts PFS in TMZ-treated patients with 
IDHmt tumors regardless of the 1p/19q status. This infor-
mation may guide clinical decision-making for individual 
patients, and in particular when considering deferring radio-
therapy in patients with a better prognosis aiming at avoid-
ing or delaying potential neurocognitive toxicity.
The limitation of the present retrospective study is the 
low statistical power and the current lack of a comparable 
validation set. Data for OS are not available yet. However, 
the development of predictive markers to allow treatment 
de-escalation are important in the future, personalizing 
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treatment strategy (single vs combined modality, choice of 
modality, novel targets) needs to be risk-adapted and is of 
particular importance in good-prognosis disease.
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